

CME INSTITUTE

collective mindfulness

[Tweetorial: Subtle Symptoms of Tardive Dyskinesia Have a Huge Impact on Early Recognition and Intervention](#)

January 19, 2023

[VIEW ON TWITTER](#)

ACCREDITATION STATEMENT

The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

FACULTY AFFILIATIONS

Martha Sajatovic MD

University Hospitals Cleveland Medical Center
Cleveland, OH

Joseph McEvoy MD

Medical College of Georgia
Augusta, GA


FINANCIAL DISCLOSURE

The CME Institute adheres to the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME). Any individuals in a position to control the content of a continuing education activity, including faculty, content developers, reviewers, staff, and others, are required to disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The CME Institute has mitigated all relevant conflicts of interest prior to the commencement of the activity. None of the individuals involved in the content have relevant financial relationships with ineligible companies except the following:

Dr Sajatovic receives consulting fees from Alkermes, Otsuka, Sunovion, Janssen, Lundbeck, Teva, Clinical Education Alliance, and Health Analytics; has conducted research sponsored by Nuromate, Otsuka, and International Society for Bipolar Disorders (ISBD); and has received publication royalties from Springer Press, Johns Hopkins University Press, Oxford Press, and UpToDate.

Dr McEvoy has received consulting fees from Clarion Healthcare and Neurocrine Biosciences; and has conducted research sponsored by Alkermes, Biogen, Boehringer Ingelheim, Millennium Pharmaceuticals, Otsuka, National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK), and National Institute of Mental Health (NIMH).



CME INSTITUTE

collective mindfulness

Michael R. Page, PharmD, RPh

Independent Medical Director/Medical Writer
Plainsboro, New Jersey

Dr. Page is a consultant for BioCentric, Inc. and American Medical Communications, Inc.

None of the other planners, reviewers, and CME Institute staff for this educational activity have relevant financial relationships with ineligible companies to disclose. All relevant financial relationships have been mitigated.



CME INSTITUTE

collective mindfulness

TWEETORIAL REFERENCES

Slide #7

Vasan S, Padhy RK. Tardive Dyskinesia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; April 30, 2022 <https://www.ncbi.nlm.nih.gov/books/NBK448207/>

Slide #8

Citrome L, Isaacson SH, Larson D, Kremens D. Tardive Dyskinesia in Older Persons Taking Antipsychotics. *Neuropsychiatr Dis Treat*. 2021;17:3127-3134. DOI: [10.2147/NDT.S328301](https://doi.org/10.2147/NDT.S328301)

Ward KM, Citrome L. Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia-Key Differences in Pathophysiology and Clinical Management. *Neurol Ther*. 2018 Dec;7(2):233-248. DOI: [10.1007/s40120-018-0105-0](https://doi.org/10.1007/s40120-018-0105-0)

Slide #9

Solmi M, Pigato G, Kane JM, Correll CU. Clinical risk factors for the development of tardive dyskinesia. *J Neurol Sci*. 2018;389:21-27. DOI: [10.1016/j.jns.2018.02.012](https://doi.org/10.1016/j.jns.2018.02.012)

Slide #10

Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. *Tremor Other Hyperkinet Mov (N Y)*. 2013 Jul 12;3:tre-03-161-4138-1. DOI: [10.7916/D88P5Z71](https://doi.org/10.7916/D88P5Z71)

Slide #11

American Psychiatric Association. The American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia. 3rd ed. <https://psychiatryonline.org/doi/book/10.1176/appi.books.9780890424841>. Accessed October 2022


Munetz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. *Hosp Community Psychiatry*. 1988;39(11):1172-1177. DOI: [10.1176/ps.39.11.1172](https://doi.org/10.1176/ps.39.11.1172)

Slide #12

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013

Slide #13

Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. *Tremor Other Hyperkinet Mov (N Y)*. 2013 Jul 12;3:tre-03-161-4138-1. DOI: [10.7916/D88P5Z71](https://doi.org/10.7916/D88P5Z71)



CME INSTITUTE

collective mindfulness

Slide #14

Ayyagari R, Goldschmidt D, Mu F, Caroff SN, Carroll B. An Experimental Study to Assess the Professional and Social Consequences of Tardive Dyskinesia. *Clin Psychopharmacol Neurosci*. 2022 Feb 28;20(1):154-166. DOI: [10.9758/cpn.2022.20.1.154](https://doi.org/10.9758/cpn.2022.20.1.154)

Caroff SN, Yeomans K, Lenderking WR, Cutler AJ, Tanner CM, Shalhoub H, Pagé V, Chen J, Franey E, Yonan C. RE-KINECT: A Prospective Study of the Presence and Healthcare Burden of Tardive Dyskinesia in Clinical Practice Settings. *J Clin Psychopharmacol*. 2020 May/Jun;40(3):259-268. DOI: [10.1097/JCP.0000000000001201](https://doi.org/10.1097/JCP.0000000000001201)

Strassnig M, Rosenfeld A, Harvey PD. Tardive dyskinesia: motor system impairments, cognition and everyday functioning. *CNS Spectr*. 2018;23(6):370-377. DOI: [10.1017/S1092852917000542](https://doi.org/10.1017/S1092852917000542)

Ward KM, Citrome L. Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia-Key Differences in Pathophysiology and Clinical Management. *Neurol Ther*. 2018 Dec;7(2):233-248. DOI: [10.1007/s40120-018-0105-0](https://doi.org/10.1007/s40120-018-0105-0)

Slide #15

McEvoy J, Gandhi SK, Rizio AA, Maher S, Kosinski M, Bjorner JB, Carroll B. Effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia. *Qual Life Res*. 2019 Dec;28(12):3303-3312. DOI: [10.1007/s11136-019-02269-8](https://doi.org/10.1007/s11136-019-02269-8)


Slide #16

Brar JS, Parepally H, Chalasani L, Gopalani A, Appel N, Chengappa KN. The impact of olanzapine on tardive dyskinetic symptoms in a state hospital population. *Ann Clin Psychiatry*. 2008;20(3):139-144. DOI: [10.1080/10401230802177755](https://doi.org/10.1080/10401230802177755)

Ricciardi L, Pringsheim T, Barnes TRE, Martino D, Gardner D, Remington G, Addington D, Morgante F, Poole N, Carson A, Edwards M. Treatment Recommendations for Tardive Dyskinesia. *Can J Psychiatry*. 2019 Jun;64(6):388-399. DOI: [10.1177/0706743719828968](https://doi.org/10.1177/0706743719828968)

Slide #17

Bhidayasiri R, Fahn S, Weiner WJ, et al. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology [published correction appears in *Neurology*. 2013 Nov 26;81(22):1968]. *Neurology*. 2013;81(5):463-469. DOI: [10.1212/WNL.0b013e31829d86b6](https://doi.org/10.1212/WNL.0b013e31829d86b6)



CME INSTITUTE

collective mindfulness

Slide #18

American Psychiatric Association. The American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia. 3rd ed.
<https://psychiatryonline.org/doi/book/10.1176/appi.books.9780890424841>. Accessed October 2022

Slide #19

Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Psychiatry*. 2017;4(8):595-604. DOI: [10.1016/S2215-0366\(17\)30236-5](https://doi.org/10.1016/S2215-0366(17)30236-5)


Slide #20

Hauser RA, Factor SA, Marder SR, et al. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. *Am J Psychiatry*. 2017;174(5):476-484. DOI: [10.1176/appi.ajp.2017.16091037](https://doi.org/10.1176/appi.ajp.2017.16091037)

Slide #21

Caroff SN, Citrome L, Meyer J, et al. A Modified Delphi Consensus Study of the Screening, Diagnosis, and Treatment of Tardive Dyskinesia. *J Clin Psychiatry*. 2020;81(2):19cs12983. Published 2020 Jan 28. DOI: [10.4088/JCP.19cs12983](https://doi.org/10.4088/JCP.19cs12983)

Nierenberg AA. Collaborating With Patients to Make Treatment Decisions Based on Benefits and Risks of Medications Associated With Tardive Dyskinesia. *J Clin Psychiatry*. 2020;81(6):NU19047BR2C. Published 2020 Nov 3. DOI: [10.4088/JCP.NU19047BR2C](https://doi.org/10.4088/JCP.NU19047BR2C)



CME INSTITUTE

collective mindfulness

GLOSSARY

AIMS	Abnormal Involuntary Movement Scale
AIM-TD	Addressing Involuntary Movements in Tardive Dyskinesia
APA	American Psychiatric Association
DISCUS	Dyskinesia Identification System Condensed User Scale
HRQoL	Health Related Quality of Life
KINECT-3	NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
VMAT2	Vesicular Monoamine Transporter 2